Anzeige
Mehr »
Lynx Broker
Login
Samstag, 19.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien
Magisch! Weg frei für die >Milliarden-Chance< im Pennystockmantel!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0BLFX ISIN: SE0001137985 Ticker-Symbol: BTPC 
Frankfurt
18.10.19
08:01 Uhr
0,216 Euro
+0,002
+0,70 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTIVE BIOTECH AB Chart 1 Jahr
5-Tage-Chart
ACTIVE BIOTECH AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,222
0,272
18.10.

Aktuelle News zur ACTIVE BIOTECH Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.09.Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington's disease will be presented at the International congress of Parkinson's disease and movement disorders197Lund Sweden, September 23, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that new data from exploratory analysis of the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will...
► Artikel lesen
08.08.Active Biotech AB reports Q2 results4
08.08.Active Biotech AB: Interim report January - June 201966Significant events during the second quarter In accordance with the Board's proposal, the Extraordinary General Meeting on April 4, 2019, resolved to approve the sale of the company's...
► Artikel lesen
Börsennews zur ACTIVE BIOTECH Aktie und weiteren Hot Stocks erhalten
23.05.Annual General Meeting of Active Biotech AB39PRESS RELEASE The Annual General Meeting of Active Biotech was held on May 23, 2019. In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid. The...
► Artikel lesen
03.05.Active Biotech: The Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference "American Academy of Neurology - AAN" in Philadelphia, PA, on May 6 201963PRESS RELEASE Lund Sweden, May 3, 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease has been selected to...
► Artikel lesen
02.05.The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board28PRESS RELEASE Lund 2 May, 2019 - Active Biotech (NASDAQ, STOCKHOLM:ACTI) announce that the Election Committee of Active Biotech AB (publ) proposes that Michael Shalmi and Uli Hacksell are...
► Artikel lesen
26.04.Annual Report 2018 Active Biotech AB (publ)34PRESS RELEASE Active Biotech's Annual Report 2018 is now available for download at www.activebiotech.com (http://www.activebiotech.com). The Annual Report will only be digitally...
► Artikel lesen
25.04.Active Biotech AB - Interim report January - March 201926First quarter in brief Active Biotech's partner NeoTX entered clinical collaboration with AstraZeneca to evaluate ANYARA ("naptumumab") in combination with IMFINZI (durvalumab)...
► Artikel lesen
24.04.Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS28PRESS RELEASE The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 23, 2019, at 5 pm at the company's...
► Artikel lesen
05.04.Active Biotech completes sale of property23PRESS RELEASE Lund Sweden, April 5 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) Active Biotech completes sale of property Active Biotech AB (publ) has today completed the sale of the...
► Artikel lesen
04.04.Extraordinary General Meeting of Active Biotech AB27PRESS RELEASE Lund Sweden, April 4 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) Extraordinary General Meeting of Active Biotech An Extraordinary General Meeting of Active Biotech AB...
► Artikel lesen
13.03.Active Biotech: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING OF ACTIVE BIOTECH AB (PUBL)24The shareholders of Active Biotech AB (publ) are invited to the Extraordinary Shareholders' Meeting to be held on Thursday April 4, 2019, at 5.00 pm in the Company's offices, Scheelevägen 22 in...
► Artikel lesen
13.03.Active Biotech has entered into an agreement regarding sale of the Company's property - extraordinary general meeting on April 4, 201953Lund Sweden, March 13 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that Active Biotech has entered into an agreement regarding sale of the Company's property Forskaren 1 in Lund...
► Artikel lesen
14.02.Active Biotech Year-end report January - December 201820Fourth quarter in brief Active Biotech communicated updated information about its financial position New data from the LEGATO-HD study presented...
► Artikel lesen
11.02.Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI (durvalumab) in the upcoming Phase 1b/2 study60PRESS RELEASE Lund Sweden, February 11 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that their partner NeoTX enters a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN)...
► Artikel lesen
01.02.Active Biotech has received an indicative bid for the property in Lund - the Board is positive42As previously reported, Active Biotech's property Forskaren 1 in Lund has been on sale for a period of time. Active Biotech has now received an indicative, non-binding bid for the property...
► Artikel lesen
10.12.18Active Biotech provides updated information about the company's financial position22PRESS RELEASE As announced in connection with the interim report for January-September 2018 Active Biotech has requested, from the bank that finances the company's property in Lund, that the...
► Artikel lesen
19.11.18Active Biotech's election committee appointed23PRESS RELEASE In accordance with a decision made by the Annual General Meeting held on May 17, 2018, the Election Committee shall comprise the representatives for the three largest shareholders...
► Artikel lesen
14.11.18Active Biotech AB - Interim report January - September 201830Third quarter in brief Active Biotech provides update on laquinimod in Huntington's disease Active Biotech regains global...
► Artikel lesen
08.11.18Active Biotech: New data from the Phase 2 LEGATO-HD study will be presented at HSG 201842PRESS RELEASE New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference HSG 2018 Lund Sweden, November 8,...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1